|
1
|
Siegel RL, Kratzer TB, Giaquinto AN, Sung
H and Jemal A: Cancer statistics, 2025. CA Cancer J Clin. 75:10–45.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gansler T, Ganz PA, Grant M, Greene FL,
Johnstone P, Mahoney M, Newman LA, Oh WK, Thomas CR Jr, Thun MJ, et
al: Sixty years of CA. Cancer J Clin. 60:345–350. 2010. View Article : Google Scholar
|
|
3
|
Soffietti R, Ahluwalia M, Lin N and Rudà
R: Management of brain metastases according to molecular subtypes.
Nat RevNeurol. 16:557–574. 2020.
|
|
4
|
El Rassy E, Botticella A, Kattan J, Le
Péchoux C, Besse B and Hendriks L: Non-small cell lung cancer brain
metastases and the immune system: From brain metastases development
to treatment. Cancer Treat Rev. 68:69–79. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vogelbaum MA, Brown PD, Messersmith H,
Brastianos PK, Burri S, Cahill D, Dunn IF, Gaspar LE, Gatson NTN,
Gondi V, et al: Treatment for brain metastases: ASCO-SNO-ASTRO
guideline. J Clin Oncol. 40:492–516. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sung KS: Clinical practice guidelines for
brain metastasis from solid tumors. Brain Tumor Res Treat.
12:14–22. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Berger A, Mullen R, Bernstein K, Alzate
JD, Silverman JS, Sulman EP, Donahue BR, Chachoua A, Shum E,
Velcheti V, et al: Extended survival in patients with
non-small-cell lung cancer-associated brain metastases in the
modern era. Neurosurgery. 93:50–59. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Berghoff AS, Ilhan-Mutlu A, Dinhof C,
Magerle M, Hackl M, Widhalm G, Hainfellner JA, Dieckmann K, Pichler
J, Hutterer M, et al: Differential role of angiogenesis and tumour
cell proliferation in brain metastases according to primary tumour
type: Analysis of 639 cases. Neuropathol Appl Neurobiol.
41:e41–e55. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fang L, Zhao W, Ye B and Chen D:
Combination of immune checkpoint inhibitors and anti-angiogenic
agents in brain metastases from non-small cell lung cancer. Front
Oncol. 11:6703132021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang X, Song M, Wang A, Zhao Y, Wei Z and
Lu Y: Microbiome crosstalk in immunotherapy and antiangiogenesis
therapy. Front Immunol. 12:7479142021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tu J, Liang H, Li C, Huang Y, Wang Z, Chen
X and Yuan X: The application and research progress of
anti-angiogenesis therapy in tumor immunotherapy. Front Immunol.
14:11989722023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sun Y, Niu W, Du F, Du C, Li S, Wang J, Li
L, Wang F, Hao Y, Li C and Chi Y: Safety, pharmacokinetics, and
antitumor properties of anlotinib, an oral multi-target tyrosine
kinase inhibitor, in patients with advanced refractory solid
tumors. J Hematol Oncol. 9:1052016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang P, Fang X, Yin T, Tian H, Yu J and
Teng F: Efficacy and safety of Anti-PD-1 plus anlotinib in patients
with advanced non-small-cell lung cancer after previous systemic
treatment failure-a retrospective study. Front Oncol.
11:6281242021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang YX, Cheng C and Zhuang HQ: The safety
and efficacy of anlotinib in combination with stereotactic
radiotherapy for the treatment of brain metastases from non-small
cell lung cancer. Zhonghua Yi Xue Za Zhi. 102:930–934.
2022.PubMed/NCBI
|
|
15
|
Dutta S, Ganguly A, Chatterjee K, Spada S
and Mukherjee S: Targets of immune escape mechanisms in cancer:
Basis for development and evolution of cancer immune checkpoint
inhibitors. Biology (Basel). 12:2182023.PubMed/NCBI
|
|
16
|
Vilariño N, Bruna J, Bosch-Barrera J,
Valiente M and Nadal E: Immunotherapy in NSCLC patients with brain
metastases. Understanding brain tumor microenvironment and
dissecting outcomes from immune checkpoint blockade in the clinic.
Cancer Treat Rev. 89:1020672020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xiao G, Liu Z, Gao X, Wang H, Peng H, Li
J, Yang L, Duan H and Zhou R: Immune checkpoint inhibitors for
brain metastases in non-small-cell lung cancer: From rationale to
clinical application. Immunotherapy. 13:1031–1051. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Spano D and Zollo M: Tumor
microenvironment: A main actor in the metastasis process. Clin Exp
Metastasis. 29:381–395. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lv B, Wang Y, Ma D, Cheng W, Liu J, Yong
T, Chen H and Wnag C: Immunotherapy: Reshape the tumor immune
microenvironment. Front Immunol. 13:8441422022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rios-Hoyo A and Arriola E: Immunotherapy
and brain metastasis in lung cancer: Connecting bench side science
to the clinic. Front Immunol. 14:12210972023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mansfield AS, Aubry MC, Moser JC,
Harrington SM, Dronca RS, Park SS and Dong H: Temporal and spatial
discordance of programmed cell death-ligand 1 expression and
lymphocyte tumor infiltration between paired primary lesions and
brain metastases in lung cancer. Ann Oncol. 27:1953–1958. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guan Z, Lan H, Cai X, Zhang Y, Liang A and
Li J: Blood-Brain barrier, cell junctions, and tumor
microenvironment in brain metastases, the biological prospects and
dilemma in therapies. Front Cell Dev Biol. 9:7229172021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Harter PN, Bernatz S, Scholz A, Zeiner PS,
Zinke J, Kiyose M, Blasel S, Beschorner R, Senft C, Bender B, et
al: Distribution and prognostic relevance of tumor-infiltrating
lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain
metastases. Oncotarget. 6:40836–40849. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Téglási V, Reiniger L, Fábián K, Pipek O,
Csala I, Bagó AG, Várallyai P, Vízkeleti L, Rojkó L, Tímár J, et
al: Evaluating the significance of density, localization, and
PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical
course of lung adenocarcinoma patients with brain metastasis. Neuro
Oncol. 19:1058–1067. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim R, Keam B, Kim S, Kim M, Kim SH, Kim
JW, Kim YJ, Kim TM, Jeon YK, Kim DW, et al: Differences in tumor
microenvironments between primary lung tumors and brain metastases
in lung cancer patients: Therapeutic implications for immune
checkpoint inhibitors. BMC Cancer. 19:192019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mehdizadeh S, Bayatipoor H, Pashangzadeh
S, Jafarpour R, Shojaei Z and Motallebnezhad M: Immune checkpoints
and cancer development: Therapeutic implications and future
directions. Pathol Res Pract. 223:1534852021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu WD, Sun G, Li J, Xu J and Wang X:
Mechanisms and therapeutic potentials of cancer immunotherapy in
combination with radiotherapy and/or chemotherapy. Cancer Lett.
452:66–70. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bader JE, Voss K and Rathmell JC:
Targeting metabolism to improve the tumor microenvironment for
cancer immunotherapy. Mol Cell. 78:1019–1033. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Darvin P, Toor SM, Nair VS and Elkord E:
Immune checkpoint inhibitors: Recent progress and potential
biomarkers. Exp Mol Med. 50:1–11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li M, Hou X, Sai K, Wu L, Chen J, Zhang B,
Wang N, Wu L, Zheng H, Zhang J, et al: Immune suppressive
microenvironment in brain metastatic non-small cell lung cancer:
Comprehensive immune microenvironment profiling of brain metastases
versus paired primary lung tumors (GASTO 1060). Oncoimmunology.
11:20598742022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Y, Chen R, Wa Y, Ding S, Yang Y, Liao
J, Tong L and Xiao G: Tumor immune microenvironment and
immunotherapy in brain metastasis from non-small cell lung cancer.
Front Immunol. 13:8294512022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Takamori S, Toyokawa G, Takada K, Shoji F,
Okamoto T and Maehara Y: Combination therapy of radiotherapy and
Anti-PD-1/PD-L1 treatment in non-small-cell lung cancer: A
mini-review. Clin Lung Cancer. 19:12–16. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Popat S, Grohé C, Corral J, Reck M,
Novello S, Gottfried M, Radonjic D and Kaiser R: Anti-angiogenic
agents in the age of resistance to immune checkpoint inhibitors: Do
they have a role in non-oncogene-addicted non-small cell lung
cancer? Lung Cancer. 144:76–84. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xie M and Su C: Microenvironment and the
progress of immunotherapy in clinical practice of NSCLC brain
metastasis. Front Oncol. 12:10062842022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Meng L, Xu J, Ye Y, Wang Y, Luo S and Gong
X: The combination of radiotherapy with immunotherapy and potential
predictive biomarkers for treatment of non-small cell lung cancer
patients. Front Immunol. 12:7236092021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Suwinski R: Combination of immunotherapy
and radiotherapy in the treatment of brain metastases from
non-small cell lung cancer. J Thorac Dis. 13:3315–3322. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen YA, Zhuang H and Wang J: The
rationale and toxicity of combined cranial radiotherapy and immune
checkpoint inhibitors in non-small cell lung cancer. Asia Pac J
Clin Oncol. 18:165–170. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xu L, Chen Y and Wang M: Efficacy and
safety of radiotherapy combined with immunotherapy for brain
metastases from lung cancer: A meta-analysis. Zhongguo Fei Ai Za
Zhi. 25:715–722. 2022.(In Chinese). PubMed/NCBI
|
|
39
|
Lastwika KJ, Wilson W III, Li QK, Norris
J, Xu H, Ghazarian SR, Kitagawa H, Kawabata S, Taube JM, Yao S, et
al: Control of PD-L1 expression by oncogenic activation of the
AKT-mTOR pathway in non-small cell lung cancer. Cancer Res.
76:227–238. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Quan Z, Yang Y, Zheng H, Zhan Y, Luo J,
Ning Y and Fan S: Clinical implications of the interaction between
PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment
of non-small cell lung cancer. J Cancer. 13:3434–3443. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Perri F, Pacelli R, Scarpati GD, Cella L,
Giuliano M, Caponigro F and Pepe S: Radioresistance in head and
neck squamous cell carcinoma: Biological bases and therapeutic
implications. Head Neck. 37:763–770. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Goedegebuure RSA, de Klerk LK, Bass AJ,
Derks S and Thijssen V: Combining radiotherapy with anti-angiogenic
therapy and immunotherapy; A therapeutic triad for cancer? Front
Immunol. 14:31072019. View Article : Google Scholar
|
|
43
|
Ikarashi D, Okimoto T, Shukuya T, Onagi H,
Hayashi T, Sinicropi-Yao SL, Amann JM, Nakatsura T, Kitano S and
Carbone DP: Comparison of tumor microenvironments between primary
tumors and brain metastases in patients with NSCLC. JTO Clin Res
Rep. 2:1002302021.PubMed/NCBI
|
|
44
|
Nanda VGY, Peng W, Hwu P, Davies MA,
Ciliberto G, Fattore L, Malpicci D, Aurisicchio L, Ascierto PA,
Croce CM, et al: Melanoma and immunotherapy bridge 2015 : Naples,
Italy. 1–5 December 2015. J Transl Med. 14:652016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Patel RR, He K, Barsoumian HB, Chang JY,
Tang C, Verma V, Comeaux N, Chun SG, Gandhi S, Truong MT, et al:
High-dose irradiation in combination with non-ablative low-dose
radiation to treat metastatic disease after progression on
immunotherapy: Results of a phase II trial. Radiother Oncol.
162:60–67. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Levis M, Gastino A, De Giorgi G, Mantovani
C, Bironzo P, Mangherini L, Ricci AA, Ricardi U, Cassoni P and
Bertero L: Modern stereotactic radiotherapy for brain metastases
from lung cancer: Current trends and future perspectives based on
integrated translational approaches. Cancers (Basel). 15:46222023.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Khan M, Zhao Z, Li X and Liao G: Anti-PD1
therapy plus whole-brain radiation therapy May Prolong PFS in
selected non-small cell lung cancer patients with brain metastases:
A retrospective study. Int J Gen Med. 14:8903–8918. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chen ZY, Duan XT, Qiao SM and Zhu XX:
Radiotherapy combined with PD-1/PD-L1 inhibitors in NSCLC brain
metastases treatment: The mechanisms, advances, opportunities, and
challenges. Cancer Med. 12:995–1006. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Guo T, Zhou Y, Liang F, Wang Z, Bourbonne
V, Käsmann L, Sundahl N, Wu AJ, Ni J and Zhu Z: Potential
synergistic effects of cranial radiotherapy and atezolizumab in
non-small cell lung cancer: An analysis of individual patient data
from seven prospective trials. Transl Lung Cancer Res. 13:126–138.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Luo S, Li P, Zhang A, Meng L, Huang L, Wu
X, Cheng H, Tu H and Gong X: G-CSF improving combined whole brain
radiotherapy and immunotherapy prognosis of non-small cell lung
cancer brain metastases. Int Immunopharmacol. 130:1117052024.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Vanneste BGL, Van Limbergen EJ, Dubois L,
Samarska IV, Wieten L, Aarts MJB, Marcelissen T and De Ruysscher D:
Immunotherapy as sensitizer for local radiotherapy. Oncoimmunology.
9:18327602020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Bendavid J and Modesto A: Radiation
therapy and antiangiogenic therapy: Opportunities and challenges.
Cancer Radiother. 26:962–967. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yang X, Ren H and Fu J: Treatment of
radiation-induced brain necrosis. Oxid Med Cell Longev.
2021:47935172021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Król K, Mazur A, Stachyra-Strawa P and
Grzybowska-Szatkowska L: Non-Small cell lung cancer treatment with
molecularly targeted therapy and concurrent radiotherapy-A review.
Int J Mol Sci. 24:58582023. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hsu HW, Wall NR, Hsueh CT, Kim S, Ferris
RL, Chen CS and Mirshahidi S: Combination antiangiogenic therapy
and radiation in head and neck cancers. Oral Oncol. 50:19–26. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lévy C, Allouache D, Lacroix J, Dugué AE,
Supiot S, Campone M, Mahe M, Kichou S, Leheurteur M, Hanzen C, et
al: REBECA: A phase I study of bevacizumab and whole-brain
radiation therapy for the treatment of brain metastasis from solid
tumours. Ann Oncol. 25:2351–2356. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Li J, He J, Cai L, Lai M, Hu Q, Ren C, Wen
L, Wang J, Zhou J, Zhou Z, et al: Bevacizumab as a treatment for
radiation necrosis following stereotactic radiosurgery for brain
metastases: Clinical and radiation dosimetric impacts. Ann Palliat
Med. 10:2018–2026. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Khan M, Zhao Z, Arooj S and Liao G:
Bevacizumab for radiation necrosis following radiotherapy of brain
metastatic disease: A systematic review & meta-analysis. BMC
Cancer. 21:1672021. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Han B, Li K, Wang Q, Zhang L, Shi J, Wang
Z, Cheng Y, He J, Shi Y, Zhao Y, et al: Effect of anlotinib as a
third-line or further treatment on overall survival of patients
with advanced non-small cell lung cancer: The ALTER 0303 phase 3
randomized clinical trial. JAMA Oncol. 4:1569–1575. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Han D, Zhang J, Bao Y, Liu L, Wang P and
Qian D: Anlotinib enhances the antitumor immunity of radiotherapy
by activating cGAS/STING in non-small cell lung cancer. Cell Death
Discov. 8:4682022. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Dirkx AE, oude Egbrink MG, Castermans K,
van der Schaft DW, Thijssen VL, Dings RP, Kwee L, Mayo KH, Wagstaff
J, Bouma-ter Steege JC and Griffioen AW: Anti-angiogenesis therapy
can overcome endothelial cell anergy and promote
leukocyte-endothelium interactions and infiltration in tumors.
FASEB J. 20:621–630. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Tran TT, Caulfield J, Zhang L, Schoenfeld
D, Djureinovic D, Chiang VL, Oria V, Weiss SA, Olino K, Jilaveanu
LB and Kluger HM: Lenvatinib or anti-VEGF in combination with
anti-PD-1 differentially augments antitumor activity in melanoma.
JCI Insight. 8:e1573472023. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ramadan WS, Zaher DM, Altaie AM, Talaat IM
and Elmoselhi A: Potential therapeutic strategies for lung and
breast cancers through understanding the anti-angiogenesis
resistance mechanisms. Int J Mol Sci. 21:5652020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Qi S, Deng S, Lian Z and Yu K: Novel drugs
with high efficacy against tumor angiogenesis. Int J Mol Sci.
23:69342022. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Fakhrejahani E and Toi M: Antiangiogenesis
therapy for breast cancer: An update and perspectives from clinical
trials. Jpn J Clin Oncol. 44:197–207. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Wu LC and Zhang WD: Clinical trials of
antiangiogenesis therapy on gastric cancer. Gastroenterol Res.
1:14–19. 2008.
|
|
67
|
Ribatti D, Vacca A, Nico B, Sansonno D and
Dammacco F: Angiogenesis and anti-angiogenesis in hepatocellular
carcinoma. Cancer Treat Rev. 32:437–444. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Giantonio BJ, Levy DE, O'Dwyer PJ, Meropol
NJ, Catalano PJ and Benson AB III; Eastern Cooperative Oncology
Group, : A phase II study of high-dose bevacizumab in combination
with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for
advanced colorectal cancer: Results from the eastern cooperative
oncology group study E2200. Ann Oncol. 17:1399–1403. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Xu J, Liu X, Yang S, Zhang X and Shi Y:
Clinical response to apatinib monotherapy in advanced non-small
cell lung cancer. Asia Pac J Clin Oncol. 14:264–269. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Ren S, He J, Fang Y, Chen G, Ma Z, Chen J,
Guo R, Lin X, Yao Y, Wu G, et al: Camrelizumab plus apatinib in
treatment-naive patients with advanced nonsquamous NSCLC: A
multicenter, open-label, single-arm, phase 2 trial. JTO Clin Res
Rep. 3:1003122022.PubMed/NCBI
|
|
72
|
Zhou C, Wang Y, Zhao J, Chen G, Liu Z, Gu
K, Huang M, He J, Chen J, Ma Z, et al: Efficacy and biomarker
analysis of camrelizumab in combination with apatinib in patients
with advanced nonsquamous NSCLC previously treated with
chemotherapy. Clin Cancer Res. 27:1296–1304. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Ou DL, Chen CW, Hsu CL, Chung CH, Feng ZR,
Lee BS, Cheng AL, Yang MH and Hsu C: Regorafenib enhances antitumor
immunity via inhibition of p38 kinase/Creb1/Klf4 axis in
tumor-associated macrophages. J Immunothera Cancer. 9:e0016572021.
View Article : Google Scholar
|
|
74
|
Huang G and Chen L: Discrepancies between
antiangiogenic and antitumor effects of recombinant human
endostatin. Cancer Biother Radiopharm. 24:589–596. 2009.PubMed/NCBI
|
|
75
|
Rani V and Prabhu A: Combining
angiogenesis inhibitors with radiation: Advances and challenges in
cancer treatment. Curr Pharm Des. 27:919–931. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Riesterer O: Angiogenesis inhibitors and
radiotherapy. Praxis (Bern 1994). 101:1031–1037. 2012.(In German).
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Sun X, Deng L and Lu Y: Challenges and
opportunities of using stereotactic body radiotherapy with
anti-angiogenesis agents in tumor therapy. Chin J Cancer Res.
30:147–156. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Park I, Yang H, Park JS, Koh GY and Choi
EK: VEGF-Grab enhances the efficacy of radiation therapy by
blocking VEGF-A and treatment-induced PlGF. Int J Radiat Oncol Biol
Phys. 102:609–618. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Dickson PV, Hamner JB, Sims TL, Fraga CH,
Ng CY, Rajasekeran S, Hagedorn NL, McCarville MB, Stewart CF and
Davidoff AM: Bevacizumab-induced transient remodeling of the
vasculature in neuroblastoma xenografts results in improved
delivery and efficacy of systemically administered chemotherapy.
Clin Cancer Res. 13:3942–3950. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Gao H, Xue J, Zhou L, Lan J, He J, Na F,
Yang L, Deng L and Lu Y: Bevacizumab radiosensitizes non-small cell
lung cancer xenografts by inhibiting DNA double-strand break repair
in endothelial cells. Cancer Lett. 365:79–88. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Li L, Feng M, Xu P, Wu YL, Yin J, Huang Y,
Tan MY and Jinyi L: Stereotactic radiosurgery with whole brain
radiotherapy combined with bevacizumab in the treatment of brain
metastases from NSCLC. Int J Neurosci. 133:334–341. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Chen YL, Huang AP, Wang CC, Chen HY, Chen
YF, Xiao F, Lu SL, Cheng JC and Hsu FM: Peri-radiosurgical
administration of bevacizumab improves radiographic response to
single and fractionated stereotactic radiosurgery for large brain
metastasis. J Neurooncol. 153:455–465. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Yang S, Sun J, Xu M, Wang Y, Liu G and
Jiang A: The value of anlotinib in the treatment of intractable
brain edema: Two case reports. Front Oncol. 11:6178032021.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Fan P, Qiang H, Liu Z, Zhao Q, Wang Y, Liu
T, Wang X, Chu T, Huang Y, Xu W and Qin S: Effective low-dose
Anlotinib induces long-term tumor vascular normalization and
improves anti-PD-1 therapy. Front Immunol. 13:9379242022.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Li PJ, Lai SZ, Jin T, Ying HJ, Chen YM,
Zhang P, Hang QQ, Deng H, Wang L, Feng JG, et al: Radiotherapy
opens the blood-brain barrier and synergizes with anlotinib in
treating glioblastoma. Radiother Oncol. 183:1096332023. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
He L, Pi Y, Li Y, Wu Y, Jiang J, Rong X,
Cai J, Yue Z, Cheng J, Li H, et al: Efficacy and safety of apatinib
for radiation-induced brain injury among patients with head and
neck cancer: An open-label, single-arm, phase 2 study. Int J Radiat
Oncol Biol Phys. 113:796–804. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Xu W, Yang M, Du X, Peng H, Yang Y, Wang J
and Zhang Y: Multifunctional nanoplatform based on sunitinib for
synergistic phototherapy and molecular targeted therapy of
hepatocellular carcinoma. Micromachines (Basel). 14:6132023.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Rahma OE and Hodi FS: The intersection
between tumor angiogenesis and immune suppression. Clin Cancer Res.
25:5449–5457. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Hu H, Chen Y, Tan S, Wu S, Huang Y, Fu S,
Luo F and He J: The research progress of antiangiogenic therapy,
immune therapy and tumor microenvironment. Front Immunol.
13:8028462022. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Kusmartsev S, Eruslanov E, Kübler H, Tseng
T, Sakai Y, Su Z, Kaliberov S, Heiser A, Rosser C, Dahm P, et al:
Oxidative stress regulates expression of VEGFR1 in myeloid cells:
Link to tumor-induced immune suppression in renal cell carcinoma. J
Immunol. 181:346–353. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Zafar MI, Zheng J, Kong W, Ye X, Gou L,
Regmi A and Chen LL: The role of vascular endothelial growth
factor-B in metabolic homoeostasis: Current evidence. Biosci Rep.
37:BSR201710892017. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Bourhis M, Palle J, Galy-Fauroux I and
Terme M: Direct and indirect modulation of T cells by VEGF-A
counteracted by anti-angiogenic treatment. Front Immunol.
12:6168372021. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Szebeni GJ, Vizler C, Kitajka K and Puskas
LG: Inflammation and cancer: Extra- and intracellular determinants
of tumor-associated macrophages as tumor promoters. Mediators
Inflamm. 2017:92940182017. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Liu QP, Chen YY, An P, Rahman K, Luan X
and Zhang H: Natural products targeting macrophages in tumor
microenvironment are a source of potential antitumor agents.
Phytomedicine. 109:1546122023. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Huang Y, Yuan J, Righi E, Kamoun WS,
Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR,
Vianello F, et al: Vascular normalizing doses of antiangiogenic
treatment reprogram the immunosuppressive tumor microenvironment
and enhance immunotherapy. Proce Natil Acad Sci USA.
109:17561–17566. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Swed B, Ryan K, Gandarilla O, Shah MA and
Brar G: Favorable response to second-line atezolizumab and
bevacizumab following progression on nivolumab in advanced
hepatocellular carcinoma: A case report demonstrating that
anti-VEGF therapy overcomes resistance to checkpoint inhibition.
Medicine (Baltimore). 100:e264712021. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Wang Q, Gao J, Di W and Wu X:
Anti-angiogenesis therapy overcomes the innate resistance to
PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models.
Cancer Immunol Immunother. 69:1781–1799. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Manegold C, Dingemans AC, Gray JE,
Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT,
Crinò L, et al: The potential of combined immunotherapy and
antiangiogenesis for the synergistic treatment of advanced NSCLC. J
Thorac Oncol. 12:194–207. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Fukumura D, Kloepper J, Amoozgar Z, Duda
DG and Jain RK: Enhancing cancer immunotherapy using
antiangiogenics: Opportunities and challenges. Nat Rev Clin Oncol.
15:325–340. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Huang Y, Kim BYS, Chan CK, Hahn SM,
Weissman IL and Jiang W: Improving immune-vascular crosstalk for
cancer immunotherapy. Nat Rev Immunol. 18:195–203. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Yaguchi T, Sumimoto H, Kudo-Saito C,
Tsukamoto N, Ueda R, Iwata-Kajihara T, Nishio H, Kawamura N and
Kawakami Y: The mechanisms of cancer immunoescape and development
of overcoming strategies. Int J Hematol. 93:294–300. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Xia L, Liu Y and Wang Y: PD-1/PD-L1
blockade therapy in advanced non-small-cell lung cancer: Current
status and future directions. Oncologist. 24 (Suppl 1):S31–S41.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Horvath L, Thienpont B, Zhao L, Wolf D and
Pircher A: Overcoming immunotherapy resistance in non-small cell
lung cancer (NSCLC)-novel approaches and future outlook. Mol
Cancer. 19:1412020. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Xu J, Gan C, Yu S, Yao S, Li W and Cheng
H: Analysis of immune resistance mechanisms in TNBC: Dual effects
inside and outside the tumor. Clin Breast Cancer. 24:e91–e102.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Khalaf K, Hana D, Chou JT, Singh C,
Mackiewicz A and Kaczmarek M: Aspects of the tumor microenvironment
involved in immune resistance and drug resistance. Front Immunol.
12:6563642021. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Dobosz P, Stępień M, Golke A and
Dzieciątkowski T: Challenges of the immunotherapy: Perspectives and
limitations of the immune checkpoint inhibitor treatment. Int J Mol
Sci. 23:28472022. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Kudo-Saito C, Ishida A, Shouya Y, Teramoto
K, Igarashi T, Kon R, Saito K, Awada C, Ogiwara Y and Toyoura M:
Blocking the FSTL1-DIP2A axis improves anti-tumor immunity. Cell
Rep. 24:1790–1801. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Codony-Servat J and Rosell R: Cancer stem
cells and immunoresistance: Clinical implications and solutions.
Transl Lung Cancer Res. 4:689–703. 2015.PubMed/NCBI
|
|
109
|
Wu L, Cheng D, Yang X, Zhao W, Fang C,
Chen R and Ji M: M2-TAMs promote immunoresistance in lung
adenocarcinoma by enhancing METTL3-mediated m6A methylation. Ann
Transl Med. 10:13802022. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Khouzam RA, Janji B, Thiery J, Zaarour RF,
Chamseddine AN, Mayr H, Savagner P, Kieda C, Gad S, Buart S, et al:
Hypoxia as a potential inducer of immune tolerance, tumor
plasticity and a driver of tumor mutational burden: Impact on
cancer immunotherapy. Semin Cancer Biol. 97:104–123. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Larroquette M, Domblides C, Lefort F,
Lasserre M, Quivy A, Sionneau B, Bertolaso P, Gross-Goupil M,
Ravaud A and Daste A: Combining immune checkpoint inhibitors with
chemotherapy in advanced solid tumours: A review. Eur J Cancer.
158:47–62. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Luo L, Liu P, Zhao K, Zhao W and Zhang X:
The immune microenvironment in brain metastases of non-small cell
lung cancer. Front Oncol. 11:6988442021. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Wu Y, Kang K, Han C, Wang L, Wang Z and
Zhao A: Single-Cell profiling comparisons of tumor microenvironment
between primary advanced lung adenocarcinomas and brain metastases
and machine learning algorithms in predicting immunotherapeutic
responses. Biomolecules. 13:1852023. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Hulsbergen AFC, Mammi M, Nagtegaal SHJ,
Lak AM, Kavouridis V, Smith TR, Iorgulescu JB, Mekary RA, Verhoeff
JJC, Broekman MLD and Phillips JG: Programmed death receptor ligand
one expression may independently predict survival in patients with
non-small cell lung carcinoma brain metastases receiving
immunotherapy. Int J Radiat Oncol Biol Phys. 108:258–267. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Hargadon KM, Johnson CE and Williams CJ:
Immune checkpoint blockade therapy for cancer: An overview of
FDA-approved immune checkpoint inhibitors. Int Immunopharmacol.
62:29–39. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Cha JH, Chan LC, Li CW, Hsu JL and Hung
MC: Mechanisms controlling PD-L1 expression in cancer. Mol Cell.
76:359–370. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Gandhi L, Rodríguez-Abreu D, Gadgeel S,
Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ,
Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic
non-small-cell lung cancer. N Engl J Med. 31:2078–2092. 2018.
View Article : Google Scholar
|
|
118
|
Paz-Ares L, Luft A, Vicente D, Tafreshi A,
Gümüş M, Mazières J, Hermes B, Şenler FC, Csőszi T, Fülöp A, et al:
Pembrolizumab plus chemotherapy for squamous non-small-cell lung
cancer. N Engl J Med. 379:2040–2051. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Yu S, Zhang S, Xu H, Yang G, Xu F, Yang L,
Chen D, An G and Wang Y: Organ-specific immune checkpoint inhibitor
treatment in lung cancer: A systematic review and meta-analysis.
BMJ Open. 13:e0594572023. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Zhou S, Ren F and Meng X: Efficacy of
immune checkpoint inhibitor therapy in EGFR mutation-positive
patients with NSCLC and brain metastases who have failed EGFR-TKI
therapy. Front Immunol. 13:9559442022. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Chu X, Niu L, Xiao G, Peng H, Deng F, Liu
Z, Wu H, Yang L, Tan Z, Li Z and Zhou R: The long-term and
short-term efficacy of immunotherapy in non-small cell lung cancer
patients with brain metastases: A systematic review and
meta-analysis. Front Immunol. 13:8754882022. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Shepard MJ, Xu Z, Donahue J, Muttikkal TJ,
Cordeiro D, Hansen L, Mohammed N, Gentzler RD, Larner J, Fadul CE
and Sheehan JP: Stereotactic radiosurgery with and without
checkpoint inhibition for patients with metastatic non-small cell
lung cancer to the brain: A matched cohort study. J Neurosurg.
133:685–692. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Khalifa J, Amini A, Popat S, Gaspar LE and
Faivre-Finn C; International Association for the Study of Lung
Cancer Advanced Radiation Technology Committee, : Brain metastases
from NSCLC: Radiation therapy in the era of targeted therapies. J
Thorac Oncol. 11:1627–1643. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Porte J, Saint-Martin C, Frederic-Moreau
T, Massiani MA, Bozec L, Cao K, Verrelle P, Otz J, Jadaud E, Minsat
M, et al: Efficacy and safety of combined brain stereotactic
radiotherapy and immune checkpoint inhibitors in non-small-cell
lung cancer with brain metastases. Biomedicines. 10:22492022.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Scoccianti S, Olmetto E, Pinzi V, Osti MF,
Di Franco R, Caini S, Anselmo P, Matteucci P, Franceschini D,
Mantovani C, et al: Immunotherapy in association with stereotactic
radiotherapy for non-small cell lung cancer brain metastases:
Results from a multicentric retrospective study on behalf of AIRO.
Neuro Oncol. 23:1750–1764. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Gagliardi F, De Domenico P, Snider S,
Roncelli F, Pompeo E, Barzaghi LR, Bulotta A, Gregorc V, Lazzari C,
Cascinu S, et al: Role of stereotactic radiosurgery for the
treatment of brain metastasis in the era of immunotherapy: A
systematic review on current evidences and predicting factors. Crit
Rev Oncol Hematol. 165:1034312021. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Enright TL, Witt JS, Burr AR, Yadav P,
Leal T and Baschnagel AM: Combined immunotherapy and stereotactic
radiotherapy improves neurologic outcomes in patients with
non-small-cell lung cancer brain metastases. Clin Lung Cancer.
22:110–119. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Dohm AE, Tang JD, Mills MN, Liveringhouse
CL, Sandoval ML, Perez BA, Robinson TJ, Creelan BC, Gray JE, Etame
AB, et al: Clinical outcomes of non-small cell lung cancer brain
metastases treated with stereotactic radiosurgery and immune
checkpoint inhibitors, EGFR tyrosine kinase inhibitors,
chemotherapy and immune checkpoint inhibitors, or chemotherapy
alone. J Neurosurg. 138:1600–1607. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Guo T, Chu L, Chu X, Yang X, Li Y, Zhou Y,
Xu D, Zhang J, Wang S, Hu J, et al: Brain metastases, patterns of
intracranial progression, and the clinical value of upfront cranial
radiotherapy in patients with metastatic non-small cell lung cancer
treated with PD-1/PD-L1 inhibitors. Transl Lung Cancer Res.
11:173–187. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Kang S, Jeong H, Park JE, Kim HS, Kim YH,
Lee DH, Kim SW, Lee JC, Choi CM and Yoon S: Central nervous
systemic efficacy of immune checkpoint inhibitors and concordance
between intra/extracranial response in non-small cell lung cancer
patients with brain metastasis. J Cancer Res Clin Oncol.
149:4523–4532. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Guo F and Cui J: Anti-angiogenesis:
Opening a new window for immunotherapy. Life Sci. 258:1181632020.
View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Yang J, Yan J and Liu B: Targeting
VEGF/VEGFR to modulate antitumor immunity. Front Immunol.
9:9782018. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Yang Y, Li L, Jiang Z, Wang B and Pan Z:
Anlotinib optimizes anti-tumor innate immunity to potentiate the
therapeutic effect of PD-1 blockade in lung cancer. Cancer Immunol
Immunother. 69:2523–2532. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Song Y, Fu Y, Xie Q, Zhu B, Wang J and
Zhang B: Anti-angiogenic agents in combination with immune
checkpoint inhibitors: A promising strategy for cancer treatment.
Front Immunol. 11:19562020. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Rivera LB, Meyronet D, Hervieu V,
Frederick MJ, Bergsland E and Bergers G: Intratumoral myeloid cells
regulate responsiveness and resistance to antiangiogenic therapy.
Cell Rep. 11:577–591. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Song JQ, Wang X, Zeng ZM, Liang PA, Zhong
CY and Liu AW: Efficacy of PD-1 inhibitors combined with
anti-angiogenic therapy in driver gene mutation negative
non-small-cell lung cancer with brain metastases. Discov Med.
35:321–331. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Altan M, Wang Y, Song J, Welsh J, Tang C,
Guha-Thakurta N, Blumenschein GR, Carter BW, Wefel JS, Ghia AJ, et
al: Nivolumab and ipilimumab with concurrent stereotactic
radiosurgery for intracranial metastases from non-small cell lung
cancer: Analysis of the safety cohort for non-randomized,
open-label, phase I/II trial. J Immunother Cancer. 11:e0068712023.
View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Cho A, Untersteiner H, Hirschmann D,
Shaltout A, Göbl P, Dorfer C, Rössler K, Marik W, Kirchbacher K,
Kapfhammer I, et al: Gamma knife radiosurgery for brain metastases
in non-small cell lung cancer patients treated with immunotherapy
or targeted therapy. Cancers (Basel). 12:36682020. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Geng Y, Zhang Q, Feng S, Li C, Wang L,
Zhao X, Yang Z, Li Z, Luo H, Liu R, et al: Safety and efficacy of
PD-1/PD-L1 inhibitors combined with radiotherapy in patients with
non-small-cell lung cancer: A systematic review and meta-analysis.
Cancer Med. 10:1222–1239. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Ma K, Guo Q and Li X: Efficacy and safety
of combined immunotherapy and antiangiogenic therapy for advanced
non-small cell lung cancer: A real-world observation study. BMC
Pulm Med. 23:1752023. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Chen B, Wang J, Pu X, Li J, Wang Q, Liu L,
Xu Y, Xu L, Kong Y, Li K, et al: The efficacy and safety of immune
checkpoint inhibitors combined with chemotherapy or anti-angiogenic
therapy as a second-line or later treatment option for advanced
non-small cell lung cancer: A retrospective comparative cohort
study. Transl Lung Cancer Res. 11:2111–2124. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Zhang S, Li S, Liu J, Yang C, Zhang L, Bao
H and Cheng Y: Comparative efficacy and safety of TKIs alone or in
combination with antiangiogenic agents in advanced EGFR-mutated
NSCLC as the first-line treatment: A systematic review and
meta-analysis. Clin Lung Cancer. 23:159–169. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Wu J, Ni T, Deng R, Li Y, Zhong Q, Tang F,
Zhang Q, Fang C, Xue Y, Zha Y and Zhang Y: Safety and efficacy of
radiotherapy/chemoradiotherapy combined with immune checkpoint
inhibitors for non-small cell lung cancer: A systematic review and
meta-analysis. Front Immunol. 14:10655102023. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Li J, Chen Y, Hu F, Qiang H, Chang Q, Qian
J, Shen Y, Cai Y and Chu T: Comparison of the efficacy and safety
in the treatment strategies between chemotherapy combined with
antiangiogenic and with immune checkpoint inhibitors in advanced
non-small cell lung cancer patients with negative PD-L1 expression:
A network meta-analysis. Front Oncol. 12:10015032022. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Liu Z, Cui L, Wang J, Zhao W and Teng Y:
Aspirin boosts the synergistic effect of EGFR/p53 inhibitors on
lung cancer cells by regulating AKT/mTOR and p53 pathways. Cell
Biochem Funct. 42:e39022024. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Qian C, Liu C, Liu W, Zhou R and Zhao L:
Targeting vascular normalization: A promising strategy to improve
immune-vascular crosstalk in cancer immunotherapy. Front Immunol.
14:12915302023. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Zhou S and Zhang H: Synergies of targeting
angiogenesis and immune checkpoints in cancer: From mechanism to
clinical applications. Anticancer Agents Med Chem. 20:768–776.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Yuan M, Zhai Y, Men Y, Zhao M, Sun X, Ma
Z, Bao Y, Yang X, Sun S, Liu Y, et al: Anlotinib enhances the
antitumor activity of high-dose irradiation combined with
anti-PD-L1 by potentiating the tumor immune microenvironment in
murine lung cancer. Oxid Med Cell Longev. 2022:54794912022.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Zhao X, Zhao R, Wen J, Zhang X, Wu S, Fang
J, Ma J, Zheng W, Zhang X, Lu Z, et al: Anlotinib reduces the
suppressive capacity of monocytic myeloid-derived suppressor cells
and potentiates the immune microenvironment normalization window in
a mouse lung cancer model. Anticancer Drugs. 34:1018–1024. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Swamy K: Vascular normalization and
immunotherapy: Spawning a virtuous cycle. Front Oncol.
12:10029572022. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Lee WS, Yang H, Chon HJ and Kim C:
Combination of anti-angiogenic therapy and immune checkpoint
blockade normalizes vascular-immune crosstalk to potentiate cancer
immunity. Exp Mol Med. 52:1475–1485. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Oliveira G and Wu CJ: Dynamics and
specificities of T cells in cancer immunotherapy. Nat Rev Cancer.
23:295–316. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Charpentier M, Spada S, Van Nest SJ and
Demaria S: Radiation therapy-induced remodeling of the tumor immune
microenvironment. Semin Cancer Biol. 86:737–747. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Xian F, Wu J, Zhong L and Xu G: Efficacy
and safety of PD1/PDL1 inhibitors combined with radiotherapy and
anti-angiogenic therapy for solid tumors: A systematic review and
meta-analysis. Medicine (Baltimore). 102:e332042023. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Sun L, Zhao Q, Wang Y, Wang Y, Zheng M,
Ding X and Miao L: Efficacy and safety of anlotinib-containing
regimens in advanced non-small cell lung cancer: A real-world
study. Int J Gen Med. 16:4165–4179. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Long YY, Chen J, Xie Y, Wang Y, Wu YZ, Xv
Y, Weng KG and Zhou W: Long-term survival with a combination of
immunotherapy, anti-angiogenesis, and traditional radiotherapy in
brain metastatic small cell lung cancer: A case report. Front
Oncol. 13:12097582023. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Schettino C, Bareschino MA, Rossi A,
Maione P, Sacco PC, Colantuoni G, Rossi E and Gridelli C: Targeting
angiogenesis for treatment of NSCLC brain metastases. Curr Cancer
Drug Targets. 12:289–299. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Gao RL, Song J, Sun L, Wu ZX, Yi XF, Zhang
SL, Huang LT, Ma JT and Han CB: Efficacy and safety of combined
immunotherapy and antiangiogenesis with or without chemotherapy for
advanced non-small-cell lung cancer: A systematic review and pooled
analysis from 23 prospective studies. Front Pharmacol.
13:9201652022. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Li D, Xu L, Ji J, Bao D, Hu J, Qian Y,
Zhou Y, Chen Z, Li D, Li X, et al: Sintilimab combined with
apatinib plus capecitabine in the treatment of unresectable
hepatocellular carcinoma: A prospective, open-label, single-arm,
phase II clinical study. Front Immunol. 13:9440622022. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Zhang B, Qi L, Wang X, Xu J, Liu Y, Mu L,
Wang X, Bai L and Huang J: Phase II clinical trial using
camrelizumab combined with apatinib and chemotherapy as the
first-line treatment of advanced esophageal squamous cell
carcinoma. Cancer Commun (Lond). 40:711–720. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Lai S, Li P, Liu X, Liu G, Xie T, Zhang X,
Wang X, Huang J, Tang Y, Liu Z, et al: Efficacy and safety of
anlotinib combined with the STUPP regimen in patients with newly
diagnosed glioblastoma: A multicenter, single-arm, phase II trial.
Cancer Biol Med. 21:433–444. 2024.PubMed/NCBI
|
|
162
|
Theelen W, Chen D, Verma V, Hobbs BP,
Peulen HMU, Aerts J, Bahce I, Niemeijer ALN, Chang JY, de Groot PM,
et al: Pembrolizumab with or without radiotherapy for metastatic
non-small-cell lung cancer: A pooled analysis of two randomised
trials. Lancet Respir Med. 9:467–475. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Gu D, Yu H, Ding N, Xu J, Qian P, Zhu J,
Jiang M, Tao H and Zhu X: A phase II study of anlotinib plus whole
brain radiation therapy for patients with NSCLC with multiple brain
metastases. Ann Med. 56:24016182024. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Li S, Yu W, Xie F, Luo H, Liu Z, Lv W, Shi
D, Yu D, Gao P, Chen C, et al: Neoadjuvant therapy with immune
checkpoint blockade, antiangiogenesis, and chemotherapy for locally
advanced gastric cancer. Nat Commun. 14:82023. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Zhai Y, Ma H, Hui Z, Zhao L, Li D, Liang
J, Wang X, Xu L, Chen B, Tang Y, et al: HELPER study: A phase II
trial of continuous infusion of endostar combined with concurrent
etoposide plus cisplatin and radiotherapy for treatment of
unresectable stage III non-small-cell lung cancer. Radiother Oncol.
131:27–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Brown PD, Jaeckle K, Ballman KV, Farace E,
Cerhan JH, Anderson SK, Carrero XW, Barker FG II, Deming R, Burri
SH, et al: Effect of radiosurgery alone vs radiosurgery with whole
brain radiation therapy on cognitive function in patients with 1 to
3 brain metastases: A randomized clinical trial. JAMA. 316:401–409.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Abdallah M, Voland R, Decamp M, Flickinger
J, Pacioles T, Jamil M, Silbermins D, Shenouda M, Valsecchi M, Bir
A, et al: Evaluation of anti-angiogenic therapy combined with
immunotherapy and chemotherapy as a strategy to treat locally
advanced and metastatic non-small-cell lung cancer. Cancers
(Basel). 16:42072024. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Reck M, Mok TSK, Nishio M, Jotte RM,
Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu
D, Moro-Sibilot D, et al: Atezolizumab plus bevacizumab and
chemotherapy in non-small-cell lung cancer (IMpower150): Key
subgroup analyses of patients with EGFR mutations or baseline liver
metastases in a randomised, open-label phase 3 trial. Lancet Respir
Med. 7:387–401. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Chen K, Xu Y, Huang Z, Yu X, Hong W, Li H,
Xu X, Lu H, Xie F, Chen J, et al: Sintilimab plus anlotinib as
second- or third-line therapy in metastatic non-small cell lung
cancer with uncommon epidermal growth factor receptor mutations: A
prospective, single-arm, phase II trial. Cancer Med.
12:19460–19470. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Shi M, Chen P, Cui B, Yao Y, Wang J, Zhou
T and Wang L: Benmelstobart plus anlotinib in patients with
EGFR-positive advanced NSCLC after failure of EGFR TKIs therapy: A
phase I/II study. Signal Transduct Targeted Ther. 9:2832024.
View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Zhang F, Chen G, Yin Y, Chen X, Nie R and
Chen Y: First-line immune checkpoint inhibitors in low programmed
death-ligand 1-expressing population. Front Pharmacol.
15:13776902024. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Lorenc P, Sikorska A, Molenda S, Guzniczak
N, Dams-Kozlowska H and Florczak A: Physiological and
tumor-associated angiogenesis: Key factors and therapy targeting
VEGF/VEGFR pathway. Biomed Pharmacother. 180:1175852024. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Patel A, Dong T, Ansari S, Cohen-Gadol A,
Watson GA, Moraes FY, Nakamura M, Murovic J, Chang SD, Hatiboglu
MA, et al: Toxicity of radiosurgery for brainstem metastases. World
Neurosurg. 119:e757–e764. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Chen WC, Baal UH, Baal JD, Pai JS, Boreta
L, Braunstein SE and Raleigh DR: Efficacy and safety of
stereotactic radiosurgery for brainstem metastases: A systematic
review and meta-analysis. JAMA Oncol. 7:1033–1040. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Shaw MG and Ball DL: Treatment of brain
metastases in lung cancer: Strategies to avoid/reduce late
complications of whole brain radiation therapy. Curr Treat Options
Oncol. 14:553–567. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Yang TJ, Wijetunga NA, Yamada J, Wolden S,
Mehallow M, Goldman DA, Zhang Z, Young RJ, Kris MG, Yu HA, et al:
Clinical trial of proton craniospinal irradiation for
leptomeningeal metastases. Neuro Oncol. 23:134–143. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Mehmi I and Hamid O: Immunotherapy of
cancer in the era of checkpoint inhibitor. Clin Exp Metastasis.
39:231–237. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Rossi G, Russo A, Tagliamento M, Tuzi A,
Nigro O, Vallome G, Sini C, Grassi M, Dal Bello MG, Coco S, et al:
Precision medicine for NSCLC in the era of immunotherapy: New
biomarkers to select the most suitable treatment or the most
suitable patient. Cancers (Basel). 12:11252020. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Chang K, Jiao Y, Zhang B, Hou L, He X,
Wang D, Li D, Li R, Wang Z, Fan P and Zhang J: MGP(+) and IDO1(+)
tumor-associated macrophages facilitate immunoresistance in breast
cancer revealed by single-cell RNA sequencing. Int Immunopharmacol.
131:1118182024. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Tímár J and Ladányi A: Immunogenomic
aspects of tumor progression. Magy Onkol. 63:173–182. 2019.(In
Hungarian). PubMed/NCBI
|
|
181
|
Albesiano E, Han JE and Lim M: Mechanisms
of local immunoresistance in glioma. Neurosurg Clin N Am. 21:17–29.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Cabezón-Gutiérrez L, Custodio-Cabello S,
Palka-Kotlowska M, Alonso-Viteri S and Khosravi-Shahi P: Biomarkers
of immune checkpoint inhibitors in non-small cell lung cancer:
Beyond PD-L1. Clin Lung Cancer. 22:381–389. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Zhou S and Yang H: Immunotherapy
resistance in non-small-cell lung cancer: From mechanism to
clinical strategies. Front Immunol. 14:11294652023. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Jing Y, Zeng H, Cheng R, Tian P and Li Y:
Advances of immunotherapy resistance and coping strategies in
non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 26:66–77.
2023.PubMed/NCBI
|
|
185
|
Zhang Y and Brekken RA: Direct and
indirect regulation of the tumor immune microenvironment by VEGF. J
Leukoc Biol. 111:1269–1286. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Li Z, Lai X, Fu S, Ren L, Cai H, Zhang H,
Gu Z, Ma X and Luo K: Immunogenic cell death activates the tumor
immune microenvironment to boost the immunotherapy efficiency. Adv
Sci (Weinh). 9:e22017342022. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Guo S, Yao Y, Tang Y, Xin Z, Wu D, Ni C,
Huang J, Wei Q and Zhang T: Radiation-induced tumor immune
microenvironments and potential targets for combination therapy.
Signal Transduct Target Ther. 8:2052023. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Sun D, Liu J, Zhou H, Shi M, Sun J, Zhao
S, Chen G, Zhang Y, Zhou T, Ma Y, et al: Classification of tumor
immune microenvironment according to programmed death-ligand 1
expression and immune infiltration predicts response to
immunotherapy plus chemotherapy in advanced patients with NSCLC. J
Thorac Oncol. 18:869–881. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Wang Y, Liu S, Yang Z, Algazi AP, Lomeli
SH, Wang Y, Othus M, Hong A, Wang X, Randolph CE, et al:
Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes
antitumor immunity and efficacy. Cancer Cell. 39:1375–1387.e6.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Caetano MS, Younes AI, Barsoumian HB,
Quigley M, Menon H, Gao C, Spires T, Reilly TP, Cadena AP, Cushman
TR, et al: Triple therapy with MerTK and PD1 inhibition plus
radiotherapy promotes abscopal antitumor immune responses. Clin
Cancer Res. 25:7576–7584. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Yeung MY, McGrath M and Najafian N: The
emerging role of the TIM molecules in transplantation. Am J
Transplant. 11:2012–2019. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Chen L, Tong F, Peng L, Huang Y, Yin P,
Feng Y, Cheng S, Wang J and Dong X: Efficacy and safety of
recombinant human endostatin combined with whole-brain radiation
therapy in patients with brain metastases from non-small cell lung
cancer. Radiother Oncol. 174:44–51. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Yang RF, Yu B, Zhang RQ, Wang XH, Li C,
Wang P, Zhang Y, Han B, Gao XX, Zhang L, et al: Bevacizumab and
gefitinib enhanced whole-brain radiation therapy for brain
metastases due to non-small-cell lung cancer. Braz J Med Biol Res.
51:e60732017. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Xu Y, Chen K, Xu Y, Li H, Huang Z, Lu H,
Huang D, Yu S, Han N, Gong L, et al: Brain radiotherapy combined
with camrelizumab and platinum-doublet chemotherapy for previously
untreated advanced non-small-cell lung cancer with brain metastases
(C-Brain): A multicentre, single-arm, phase 2 trial. Lancet Oncol.
26:74–84. 2025. View Article : Google Scholar : PubMed/NCBI
|
